Thu, February 5, 2009
Wed, February 4, 2009
Tue, February 3, 2009
Mon, February 2, 2009
Sun, February 1, 2009
Sat, January 31, 2009
Fri, January 30, 2009
[ Fri, Jan 30th 2009 ] - Market Wire
Progen-Avexa Merger Update
Thu, January 29, 2009
Wed, January 28, 2009
Tue, January 27, 2009
[ Tue, Jan 27th 2009 ] - Market Wire
SCOR: SCOR sets up Zurich Hub
Mon, January 26, 2009
Sun, January 25, 2009
Fri, January 23, 2009

Biodel to Report First Quarter Fiscal Year 2009 Results and Top Line Results of Bioequivalence Study on February 5, 2009


//health-fitness.news-articles.net/content/2009/ .. -of-bioequivalence-study-on-february-5-2009.html
Published in Health and Fitness on Friday, January 30th 2009 at 13:28 GMT, Last Modified on 2009-01-30 13:28:43 by Market Wire   Print publication without navigation


DANBURY, Conn.--([ BUSINESS WIRE ])--Biodel Inc. (Nasdaq: BIOD) will issue its fiscal first quarter 2009 financial results on February 5, 2009. The company will also discuss the top line results of its study testing the bioequivalence of the 25 IU two part formulation and 100 IU one part liquid formulation of VIAject(TM) in patients with Type 1 diabetes. Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress.

February 5, 2009 schedule:

          4:00 pm EST:       Q1 fiscal 2009 results will be
distributed by Business Wire
4:50 pm EST: Conference call participants should dial:
+1 877-857-6161 (United States) or
+1 719-325-4802 (International)
5:00 pm EST: Conference call begins

Interested parties may access a live audio webcast of the conference call in the investor section of Biodel's website at [ http://www.biodel.com ]. The audio webcast will be archived and available for replay through the website.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed using VIAdelTM technology, which reformulates existing FDA-approved peptide drugs. For further information regarding Biodel, please visit the company's website at [ www.Biodel.com ].

BIOD-G


Publication Contributing Sources